Affiliation:
1. Drug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University-Sofia, 1000 Sofia, Bulgaria
Abstract
The identification and characterization of immunogenic tumor antigens are essential for cancer vaccine development. In light of the impracticality of isolating and evaluating each putative antigen individually, in silico prediction algorithms, particularly those utilizing machine learning (ML) approaches, play a pivotal role. These algorithms significantly reduce the experimental workload necessary for discovering vaccine candidates. In this study, we employed six supervised ML methods on a dataset comprising 212 experimentally validated human tumor peptide antigens and an equal number of non-antigenic human peptides to develop models for immunogenicity prediction. These methods encompassed k-nearest neighbor (kNN), linear discriminant analysis (LDA), quadratic discriminant analysis (QDA), support vector machine (SVM), random forest (RF), and extreme gradient boosting (XGBoost). The models underwent validation through internal cross-validation within 10 groups from the training set and were further assessed using an external test set. Remarkably, the kNN model demonstrated superior performance, recognizing 90% of the known immunogens in the test set. The RF model excelled in the identification of non-immunogens, accurately classifying 93% of them in the test set. The three top-performing ML models according to multiple evaluation metrics (SVM, RF, and XGBoost) are to be subsequently integrated into the new version of the VaxiJen server, facilitating tumor antigen prediction through a majority voting mechanism.
Funder
the Bulgarian national plan for recovery and resilience through the Bulgarian National Science Fund
the Science and Education for Smart Growth Operational Program
Reference38 articles.
1. Immunogenicity of cancer cells: An overview;Singh;Cell Signal.,2024
2. Innate immune recognition of cancer;Woo;Annu. Rev. Immunol.,2015
3. In situ vaccine, immunological memory and cancer cure;Tsung;Hum. Vaccines Immunotherap.,2016
4. Okada, M., Shimizu, K., and Fujii, S.I. (2022). Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. Int. J. Mol. Sci., 23.
5. An overview of bioinformatics tools for epitope prediction: Implications on vaccine development;J. Biomed. Inform.,2015